Rare diseases
Investigational molecules
Locations
Recombinant mutated extracellular domain of the human acetylcholine receptor subunit alpha1 is an investigational protein-based substance. It is classified as a protein of non-chemical origin and is being developed as a potential treatment for myasthenia gravis. The substance has no marketing authorisation in the product records and is therefore not an approved medicine.[1]
The European Medicines Agency granted orphan designation EU/3/19/2187 on 25 July 2019 to Toleranzia AB, Sweden, for this substance in the treatment of myasthenia gravis.[2] Orphan designation is given to medicines intended for rare diseases; at the time of designation myasthenia gravis affected approximately 1.7 in 10,000 people in the European Union, equivalent to around 88,000 people.[2]
Myasthenia gravis is an autoimmune disorder in which the immune system attacks and damages acetylcholine receptors on muscle cells. For a muscle to contract, a substance called acetylcholine is released from a nerve and attaches to the acetylcholine receptors on the muscle cells. In myasthenia gravis, because of the damage to these receptors, the muscles cannot contract normally.[2]
The recombinant mutated extracellular domain of the human acetylcholine receptor subunit alpha1 is designed as an immune tolerising agent. The aim of this approach is to induce immune tolerance, meaning the immune system becomes less reactive to the acetylcholine receptor, rather than broadly suppressing the immune system. The registered trial describes the substance as TOL2, an immune tolerising agent.[1]
The substance is formulated as a solution for infusion and is given by intravenous administration.[1] In the registered trial, the substance is administered intravenously alongside other medicines including prednisolone tablets, normal human immunoglobulins for intravascular administration, glucose solutions, and albumin.[1]
One trial is registered in the EU Clinical Trials Information System under the number 2024-515627-10-00. It is a double-blind, randomised, placebo-controlled, first-in-human Phase 1/2a multi-centre trial designed to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 in patients with generalised myasthenia gravis.[1]
The trial plans to enrol 55 participants and its status is authorised.[1] The primary outcomes focus on safety: the incidence and severity of adverse events using Common Terminology Criteria for Adverse Events version 5.0, with special attention to exacerbation of myasthenia gravis or myasthenic crisis, immune-complex related adverse reactions, and cytokine release syndrome, which are considered adverse events of special interest. Other primary outcomes include local tolerability reactions at the infusion site, signs of vascular toxicity, changes in vital signs, electrocardiogram findings, safety laboratory parameters, physical examination findings, and use of concomitant medications including rescue medication.[1]
The trial specifically targets AChR antibody seropositive myasthenia gravis patients.[1] Because the trial is first-in-human, no efficacy results are available yet; the main purpose is to establish safety and tolerability in people.[1]
Because the substance is still in early clinical development, no side effect profile has been established from completed trials. The registered trial is designed to detect adverse events of special interest, including exacerbation of myasthenia gravis or myasthenic crisis, immune-complex related adverse reactions, and cytokine release syndrome.[1] The published research article describes the substance as a promising new drug candidate for treatment of myasthenia gravis but does not report a side effect profile from human trials.[3]
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
